Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands. Show More...
-
Website https://www.pharming.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 0.92 EUR
-
Last Updated 29-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share EUR -1.88 -0.36 -0.33 -0.07 -0.010 -0.02 -0.04 -0.15 0.03 0.05 0.06 Dividends EUR Payout Ratio % * Shares Mil 27.0 47.0 74.0 215.0 396.0 409.0 415.0 500.0 654.0 674.0 697.0 Book Value Per Share * EUR 0.28 0.04 -0.11 0.04 0.06 0.03 0.010 0.08 0.14 0.18 Free Cash Flow Per Share * EUR -0.47 -0.31 -0.28 -0.02 -0.04 -0.010 -0.04 0.02 0.08 0.06 Return on Assets % -107.79 -55.19 -116.0 -62.42 -13.24 -17.56 -19.01 -54.58 13.13 16.35 15.05 Financial Leverage (Average) 3.43 6.27 1.86 2.42 4.62 8.84 3.47 2.18 2.63 Return on Equity % -415.39 -353.53 -33.09 -37.1 -68.36 -345.62 62.05 43.5 41.02 Return on Invested Capital % -176.29 -220.45 -30.05 -27.98 -20.74 -65.75 30.42 30.66 19.76 Interest Coverage -11.09 -82.77 -8.28 -3.58 -31.95 -79.3 -3.89 -4.04 1.06 4.91 Current Ratio 3.02 1.62 0.94 1.9 3.3 3.79 1.21 1.51 1.4 1.05 4.03 Quick Ratio 2.09 0.77 0.63 1.35 2.38 2.55 0.83 1.17 1.16 0.87 3.7 Debt/Equity 0.24 0.03 0.53 1.49 3.14 0.61 0.04 1.09